Cyclenium Pharma Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cyclenium Pharma Inc.
German anti-infectives firm AiCuris partners to develop new class of Artilysin antimicrobials that rapidly burst bacterial cells and could have an improved resistance profile.
Emerging Company Profile: Cyclenium Pharma spoke with Scrip about macrocyclic drug discovery, which covers the molecular space between traditional small molecules and large bio-molecules, to capture the pharmacological properties of larger peptides/proteins in metabolically stable small molecules and proven in a broad range of target classes.
Vertex hopes to develop CTX001 as a treatment for sickle cell disease and beta thalassemia. Allergan adds stalled uterine fibroid candidate in buyout of troubled Repros, Juno licenses multiple myeloma candidate from Lilly.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2015.